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have been shown to have clear prognostic value in untreated patients 
and to offer tools for monitoring ongoing therapeutic efficacy. 
These changes have produced optimism regardmg the longer term 
management of HIV and the application of these new finding in 
clinics has been rapid. Pending more definitive trial results, patients 
and clinicians need to develop skills in strategic planning of such 
therapies, and in their refinement as new events and data arise. 
T h  presentation will ou the  some principles regardmg critical 
treatment choices: when to start? what to start? what to star t?  why 
and when to change? what to change to? when and why to stop? 
These seek to be simple and practical, and can to shaped to patient 
and chic ian preferences, and in the light of new data. 
The Role of Resistance and Dynamics of HIV in 
Antiviral Therapy 
D.D. Richman. University of Calgornia San Diego and Sun Diego 
Weram Afiirs Medical Center, LOJolla, c4, USA 
Progress in our understanding of the dynamics of HIV replication 
and of HIV drug resistance are providing fundamental new insights 
into the pathogenesis of HIV infection and an increasingly ratio- 
nal approach to its effective chemotherapy. The source of plasma 
virus, its relationship to loss of immune function, the magnitude of 
virus replication and the turnover rates of virus pools are becoming 
defined and provide parameters for chemotherapeutic intervention. 
The rates of generation of genetic variants, the pre-existence of re- 
sistant mutan$ and the factors needed to suppress the emergence 
of drug resistance are also becoming defined to guide chemothera- 
peutic strategies. These insigha and the unresolved issues requiring 
further clarfication will be summarized in this presentation. 
Future Targets for HIV Antiviral Therapy 
J.€? Levy. F 
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Neutralization of Bacterial Products: 
Crossreactive Anti-LPS Monoclonal Antibodies 
E.Th. Rietschel, EE. di Padova, R. Barclax H. Brade, 
D. Heumann. Research Center Bontel, CenterJor Medicine and 
Biosciences, 0-23845 Borstel, Germany 
Bacterial components such as endotoxins, exotoxins, peptidoglycan, 
lipoteichoic acid, and lipoprotein express a variety of biological ef- 
fects in lugher organisms. Among these components, endotoxins 
(hpopolysaccharides, LPS) are of particular biomedical importance. 
They not only constitute the 0-antigens of Gram-negative bacteria 
but are also essenhal for microbial viabikty and play an important 
role in the pathogenesis and toxic manifestations of bacterial infec- 
tion. Chemical characterization of Merent LPS have revealed com- 
mon structural features. The inner core region of LPS shows a high 
degree of similarity among Escherichia wli, Salmonella enterica, and 
Shigella serotypes. Among a large number of broadly crossreactive 
murine anti-core LPS Mab one of these (WN1 222-5; IgG2ak) has 
been selected and chimerized into a human IgGlk (SDZ 219-800). 
In ELISA and in immunoblots on purified LPS both SDZ 219-800 
and WNl 222-5 show a strong reactivity with all smooth LPS from 
E. roli and S. entm'ca semtypes. SDZ 219-800 and WNl 222-5 in- 
hibit in uivo the release of IL-6 and TNF and then neutralize the 
pyrogenic activity of E. coli LPS and protect mice from lethality. 
In addition, both Mab exhibit protective activity in a murine E .  
coli 0111 mfection model. Due to their broad reactivity and neu- 
aaliang characteristics these Mab represent potential candidates for 
immunotherapy of patients sutfering from endotoxemia and sepsis. 
)595/ The Therapeutic Role of G-CSF in Severe 
Infections in Non-Neutropenic Patients: Current 
Status and Future Prospects 
R.K. Root. Univ. of Wash., Seanle, WA, U S A  
G-CSF is a myelopoietic colony stimulating factor that is spe- 
d i c  for granulocytes. Administration of rGCSF (Filgrastim) to 
non-neutropenic subjects can expand the granulocyte (PMN) pool 
by almost 10-fold and can enhance the microbicidal functions of 
PMNs. Successful results in non-neutropenic animal models of in- 
fection, including sepsis and septic shock, have led to clinical studies 
of the utility of Filgrastim as an adjunct to antunicrobial therapy in 
patients with communiry acquired pneumonia (CAP), nosocomial 
pneumonia, neonatal sepsis, or systemic fungal infections. 
Results A large (756 patients) s t u d y  in patients with CAP has 
been completed. Mortality was low (6%) in both treated and placebo 
groups. Not only was Filgrastim well tolerated, but the incidence of 
organ failures, includmg ARDS, DIC and septic shock was sign& 
candy reduced as well as empyemas. Muldobar pneumonia patients 
had reduced lengths of stay in the ICU and more rapid resolution of 
infiltrates. 
Conclusions: Filgrastim administration to nonneutropenic pa- 
tients with CAP is safe and reduced infectious complications. Cur- 
rent studies focus on patients with pneumonia and septic shock or 
those with multilobar CAP to better define the patient groups most 
likely to benefit from G-CSF therapy. 
Is96/ Cytokine Manipulation in Patients with Sepsis 
J. Cohen. Department oflnferous Diseases, Rqal Postgraduate Medic51 
Srhool, London, UK 
Objectives: To critically review the current status of clinical trials in 
sepsis involving manipulation of the cyrokine cascade. Data Analysis: 
Despite the large amount of predinical data implicating cytokines as 
important medntors of sepsis, early clinical t rds  were driappoint- 
ing and led to considerable pessimism that cytokine-based strategies 
would ever have a chid role. Although it is still too soon to be 
sure, emerging data h m  the NORASEPT/INTERSEFT studtes 
and from the trial of the p 5 5 - s T m  suggest that a more encour- 
aging view m y  be justified. A crucial question will be whether 
these agents are active in all septic patients or just in subsets, and if 
so, whether those subgroups can be identhed pmspectively. Other 
strategies which are still at an earlier stage of development include 
the use of cytohes such as IL-10, which downregulate the in- 
flammatory response, or IL-12, which have a more subtle role in 
immunomodulation. 
lmmunomodulation for Severe Sepsis and Septic 
Shock What is the Future? 
J.L. Vincent. B 
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